Non-Retatrutide Research Peptides: Dubai Evidence Map
A verification-first reference map for the non-retatrutide research compounds covered in this library: GLOW, SS-31, AOD-9604, PT-141, CJC-1295 + Ipamorelin, BPC-157, TB-500, BPC-157 + TB-500, GHK-Cu, KPV, MOTS-C, Tesamorelin, and HCG. The focus is compound identity, what purity documentation exists, and where the published evidence stops.
Update History ▾
July 14, 2026: Reference-table refresh across the non-retatrutide compound set.
June 14, 2026: Initial publication, built from the non-retatrutide research-compound cluster and authoritative compound sources.
Research-use-only framing applied throughout in line with Remy editorial standards.
The non-retatrutide set is best read as a group of research-use compounds, not as a clinical recommendation set. Thirteen compounds and blends are covered across this library. They are documented against a >99% HPLC line standard, and — unlike the retatrutide line — no public batch-specific Janoshik certificate is published for each of them. That distinction is the point of this page: it maps the research guides, evidence anchors, and RUO boundaries in one place, and says plainly where documentation stops.
What Counts as Non-Retatrutide Here?
For this article, non-retatrutide means every research compound covered in this library outside the retatrutide pen and vial line. That includes single-compound research vials such as BPC-157, TB-500, GHK-Cu, SS-31, MOTS-C, AOD-9604, KPV, PT-141, and Tesamorelin, plus blends such as the GLOW pen, CJC-1295 + Ipamorelin, and BPC-157 + TB-500.
The article is designed as a parent map. Use it to understand the category, then open the linked research guide for compound-specific identity and evidence boundaries.
Compound Reference Map: Format, Class, and Guide
The table below maps each non-retatrutide compound to its documented research format, its compound class, and the research guide that carries the evidence detail.
| Compound | Research format | Compound class | Research guide |
|---|---|---|---|
| GLOW 70mg Pen | 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 prefilled pen | Three-peptide cosmetic-research blend | GLOW pen click reference |
| SS-31 10mg and 50mg | Mitochondrial-targeted tetrapeptide vial formats | Mitochondria-targeted tetrapeptide | SS-31 / elamipretide research |
| AOD-9604 10mg | hGH fragment-derived peptide vial | hGH C-terminal fragment analogue | AOD-9604 research review |
| PT-141 10mg | Melanocortin analog peptide vial | Melanocortin receptor agonist | PT-141 melanocortin research |
| CJC-1295 + Ipamorelin | 5mg + 5mg combined lyophilized research blend | GHRH analogue + GH secretagogue | CJC + Ipamorelin guide |
| BPC-157 10mg | Synthetic pentadecapeptide vial | Body Protection Compound fragment | BPC-157 research review |
| TB-500 10mg | Synthetic thymosin beta-4 fragment vial | Actin-binding thymosin fragment | TB-500 research review |
| BPC-157 + TB-500 | 5mg + 5mg combined lyophilized research blend | Two-peptide repair-model blend | Blend mechanism guide |
| GHK-Cu 50mg | Copper-binding tripeptide vial | Copper-binding tripeptide | GHK-Cu research guide |
| KPV 10mg | Lys-Pro-Val tripeptide vial | Alpha-MSH C-terminal tripeptide | KPV peptide research |
| MOTS-C 10mg | Mitochondrial-derived 16-residue peptide vial | Mitochondrial-derived peptide | MOTS-C metabolic research |
| Tesamorelin 10mg | GHRH analog peptide vial | GHRH analogue | Tesamorelin research review |
| HCG 5000iu | Chorionic gonadotropin reference-format vial | Glycoprotein gonadotropin | HCG gonadotropin reference |
How to Read the Purity Claim
The key distinction is line-standard purity versus public batch-specific COA proof. The retatrutide pages carry published batch-specific Janoshik records tied to a named batch ID. The non-retatrutide set is documented differently: it is described against a >99% HPLC line standard, and no public batch-specific Janoshik certificate is published for each of those compounds.
That distinction matters, because a line standard and a lot file are not the same evidence. A line standard describes a specification; a batch certificate reports what one specific lot measured. Only the second can be re-verified. For the published records, use the COA library, the verification walkthrough, and official contact verification.
| Proof layer | What Remy can say | What Remy should not imply |
|---|---|---|
| Line-standard HPLC | Non-reta research peptides are documented against a >99% HPLC line standard. | That every non-reta compound has a public batch-specific Janoshik file posted today. |
| Published batch-specific COA | Use where a named public report exists, such as the published retatrutide batch records. | Do not transfer retatrutide COA proof onto non-reta compounds. |
| Compound identity | Sequence class, format, and the literature that anchors identity. | Identity evidence is not efficacy evidence — the two are cited separately here. |
Evidence Map and Translation Limits
The source ledger below anchors compound identity and research context. It does not convert any catalog item into a human-use or veterinary-use product.
| Compound or group | What the literature anchors | Research-use boundary |
|---|---|---|
| BPC-157 | Recent reviews describe BPC-157 as a synthetic Body Protection Compound peptide with a literature base weighted toward preclinical and review-level findings.[1] | Identity and evidence context only; no outcome claims. |
| TB-500 / thymosin beta-4 fragment | Thymosin beta-4 and actin-binding fragments are studied around actin dynamics and tissue-repair models.[2] | Useful for mechanism framing, not a healing claim. |
| GHK-Cu | GHK-Cu is discussed as a copper-binding tripeptide with gene-expression and tissue-remodeling research context.[3] | Do not translate topical/cellular literature into personal-use instructions. |
| MOTS-C | MOTS-C is a mitochondrial-derived peptide encoded in the mitochondrial genome and studied through metabolic-signaling pathways.[4] | Research signaling context only; no metabolic outcome promise. |
| SS-31 / elamipretide | SS-31 is a mitochondria-targeted tetrapeptide studied for interactions with lipid bilayers and mitochondrial surface electrostatics.[5] | Mechanism language should stay mitochondrial-research framed. |
| AOD-9604 | AOD-9604 is identified in analytical literature as an hGH C-terminal fragment-derived peptide, with detection and in-vitro metabolism work published.[6] | Use identity and analytical context; avoid weight-management claims. |
| CJC-1295 + Ipamorelin | CJC-1295 is a long-acting GHRH analog studied for GH/IGF-1 signaling, while ipamorelin is a selective growth hormone secretagogue in the GHRP family.[7][8] | GH-axis biology only; no body-composition, anti-aging, or protocol claims. |
| KPV | KPV is the Lys-Pro-Val C-terminal tripeptide sequence of alpha-MSH, studied in immune-signaling models.[9] | Use alpha-MSH fragment identity; avoid disease or inflammation promises. |
| PT-141 / bremelanotide | FDA label material identifies bremelanotide as a melanocortin receptor agonist and sets strict approved-use boundaries for the regulated drug product.[10] | A research vial is not an FDA-approved product or personal-use guide. |
| Tesamorelin | FDA label material identifies tesamorelin as a GHRH analog in the regulated EGRIFTA SV drug context.[11] | Regulated-drug label context does not authorize an RUO vial for use. |
| HCG | DailyMed label material describes chorionic gonadotropin as a polypeptide hormone with alpha and beta subunits in regulated drug products.[12] | Remy's HCG page is a reference-format research listing, not a clinical guide. |
| Tirzepatide | Peer-reviewed SURMOUNT-1 literature anchors tirzepatide as a dual GIP/GLP-1 receptor agonist in regulated obesity research.[13] | Use compound identity and published-study context only on RUO catalog surfaces. |
Where to Look Next
Each page in the non-retatrutide cluster has a clear role. Use this map to get oriented, then follow the path that matches what you need.
- Orienting in the library: use the research index, the GLOW pen reference, and this non-reta map.
- Checking purity and proof: use Peptide COA & HPLC Purity Guide, COA Library, and Contact Verification.
- Reading the evidence: use the specific research guide for BPC-157, TB-500, SS-31, AOD-9604, MOTS-C, KPV, PT-141, CJC-1295 + Ipamorelin, Tesamorelin, HCG, Tirzepatide, or GLOW.
- Handling and storage: use Bacteriostatic Water Guide and Peptide Stability & Storage Guide.
What This Page Does Not Claim
This page supports discovery and verification for non-retatrutide research compounds. It does not claim that any product is intended for human administration, veterinary use, diagnosis, treatment, prevention, disease management, personal protocols, or outcomes. Evidence summaries are included to help researchers identify compounds and understand the limits of published literature, not to suggest use.
Where public label or study sources are cited, those sources are used only to anchor compound identity, mechanism class, or regulated-product boundaries. They do not change the framing applied throughout: For in-vitro laboratory research only. Not for human or veterinary use.
FDA PCAC meeting concluded July 24, 2026
The FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24 has concluded. The official agenda covered BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. Committee recommendations are advisory: they are not drug approvals or final agency rules. FDA presentation materials were available at this review, but an official consolidated vote summary or minutes were not retrieved, so this page does not present exact tallies as FDA-confirmed. Source: FDA meeting page and materials.
Our Research Standards
This guide draws on the compound-specific research guides in this library, PubMed-indexed studies, FDA label documents, DailyMed label material, and Remy editorial compliance standards. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
Non-Retatrutide Research FAQ
What is a non-retatrutide research peptide in this library?
Non-retatrutide research peptides are the compounds covered here outside the retatrutide pen and vial line: GLOW, SS-31, AOD-9604, PT-141, CJC-1295 + Ipamorelin, BPC-157, TB-500, BPC-157 + TB-500, GHK-Cu, KPV, MOTS-C, Tesamorelin, and HCG. Each is documented for in-vitro laboratory research only.
Which non-retatrutide compounds have their own research guide?
All thirteen. Each row of the reference map above links to the guide that carries compound identity, mechanism class, and the published evidence boundary for that compound. The guides are the detail layer; this page is the index.
Does line-standard HPLC purity mean a public batch-specific COA is posted?
No. The non-retatrutide set is documented against a greater-than-99% HPLC line standard, but no public batch-specific Janoshik certificate is posted for each of those compounds. A line standard describes a specification; a batch certificate reports what one named lot measured, and only the second can be independently re-verified.
Is this article a human-use or veterinary-use guide?
No. This article is a research-use reference map. It does not provide human-use, veterinary-use, diagnostic, treatment, disease-management, administration, or personal protocol guidance.
Which page should researchers read next?
Use this article as the parent map, then open the compound-specific research guide for identity, evidence boundaries, and the limits of the published literature. For documentation questions, continue to the peptide COA and HPLC purity guide.
Sources
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. PMID: 40789979↑
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003. PMID: 12581423↑
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. PMID: 29986520↑
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID: 25738459↑
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID: 32273339↑
- Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2014. PMID: 25208511↑
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683↑
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822↑
- Dissection of the anti-inflammatory effect of the core and C-terminal tripeptide sequences of alpha-melanocyte-stimulating hormone. Journal of Pharmacology and Experimental Therapeutics. 2003. PMID: 12750433↑
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. Revised June 2019. accessdata.fda.gov↑
- U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) prescribing information. Revised February 2024. accessdata.fda.gov↑
- DailyMed. Chorionic Gonadotropin kit drug label information. dailymed.nlm.nih.gov↑
- Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. nejm.org↑
For the full compound library, use the research index. For wider source verification, continue to the peptide COA guide and official contact verification.